Oxygen plays a central role in cardiac energy metabolism. At high altitude where the ambient oxygen level is low, we found EDNRB is associated with human hypoxia adaptation. Our subsequent study in global heterozygous knockout mice (Ednrb −/+ ) revealed that cardiac function was conserved in these mice when exposed to extreme hypoxia. The major goal of this study was (i) to determine the functional role of cardiomyocyte EdnrB in maintaining cardiac function under hypoxic stress and (ii) to validate the phenotypes we detected in Ednrb −/+ mice using EDNRB blockers. Unlike the global knockouts, cardiac-specific heterozy-
Introduction
Humans adapted to high-altitude (HA) environment are anticipated to have certain favorable variants, accumulated in their genome due to their long habitation in harsh hypoxic environments. Through whole genome sequencing, we were able to identify DNA regions and candidate genes, under Bselection [ 1, 2] . Since better therapeutic modalities for diseases involving hypoxia and ischemia in their pathogenesis can be developed by understanding mechanisms of HA adaptation, we have identified Endothelin receptor type B (EDNRB), as one of the candidate genes from the Ethiopian HA adapted population [1] . More recently, we have focused on validating the role of EDNRB in hypoxia tolerance in EdnrB knockout (KO) mice [3] . We found that a lower level of EdnrB contributes to the sustenance of a steady cardiovascular response to various degrees of hypoxia, even severe hypoxia of 5% O 2 . The heterozygote EdnrB (EdnrB −/+ ) mice were maintaining higher cardiac output (CO), peripheral perfusion, and better O 2 delivery to vital organs [3] . Together with the human study, EDNRB seems to play a key role in hypoxia tolerance.
In parallel, there has been considerable interest in the endothelin system because of its role in development of diseases and pathological conditions and also because the receptors (EdnrA and EdnrB) are important target for developing drugs for treatment. Cardiac hypoxia tolerance in EdnrB −/+ mice is interesting from several points of view. First, the HA exposure itself is recognized as a cardiac stress [4] and a conventional approach for adaptation to such environment would be to cope with such stress. And as we noticed in the EdnrB −/+ mice, downregulating EDNRB is a good example. Second, endothelin-1 (Edn1), the ligand that binds to both receptors, increases during HA exposure [5] and lead to pulmonary hypertension. Third, the receptor antagonist Bosentan, although non-specific, is given to reduce pulmonary artery pressure [6] . Fourth, the improvements post receptor antagonist treatment likely occurs through blocking EdnrB because in spite of the higher ratio of EDNRA/EDNRB (4 to 1) in the heart [7] , KO studies have ruled-out any important role of EdnrA in maintaining cardiac function [8] . And when Bosentan treatment during septic shock improves cardiac performance and microcirculatory blood flow [9, 10] , the specific binding of this antagonist to EdnrB can be viewed as a major contributor. And lastly, the phenotype that describes EdnrB −/+ mice as Bhypoxia tolerant^was directly related to cardiac function, e.g., blood pressure (BP), CO, contractility etc., or its downstream mechanism/s, e.g., lactate levels, O 2 perfusion [3] . Based on this evidence, we hypothesized that by lowering EdnrB expression in the heart, either directly by using tissue-specific KO or specific blockers, these mice would be able to demonstrate significant tolerance to acute hypoxia. In the current study, we systematically confirmed our hypothesis, first by generating cardiomyocyte-specific EdnrB KO mice (both heterozygote (EdnrB flox/+ ) and homozygote (EdnrB flox/ flox )), exposing them to acute hypoxia, and then measuring cardiac functions. Simultaneously, we also treated adult C57BL/6 J mice with Bosentan (a dual endothelin receptor blocker which blocks both EDNRA and EDNRB) and BQ-788 (EDNRB-specific blocker) and measured their cardiovascular tolerance to hypoxia.
Materials and methods

Generation of EdnrB KO and its validation
All animal care and handling was performed according to the NIH guidelines and protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the University of California San Diego (UCSD), USA. Generation of EdnrBLoxP (EdnrB flox/flox ) mice has been previously detailed [11] . Prof. David Webb, Univ. Edinburgh and Prof. Donald Kohan, Univ. Utah, kindly provided these mice. Briefly, the LoxP sequence was inserted within introns 2 and 4 (flanking exons 3 and 4) of EdnrB gene (Fig. 1a) . Earlier reports suggested that exon 3 was crucial as there was an amino acid encoded across a splice junction [12] . Subsequent sequencing confirmed no mutations within LoxP sites and no known phenotype related to EdnrB disruption, e.g., abnormality of pigmentation, gut development, litter size, or mortality rate. These mice were crossed with αMHC-MerCreMer (Myh6-cre, stock# 005650, Jackson Lab) and selected for cre'+' F1 progeny. Subsequently, they are inbred to generate cardiac-specific EdnrB homozygote and heterozygote KO mice. A schematic of the breeding strategy and its validation using PCR is provided in Fig. 1b, c. For the hypoxia experiments, we used cre'+' mice, both EdnrB flox/+ and EdnrB flox/flox and compared with cre'−' EdnrB flox/+ mice. All the mice were treated in advance with 3 × 30 mg/kg of tamoxifen.
Pharmacological validation by EDNRB blockers
Studies were performed in adult (> 3 months) male C57BL/6 J mice (Stock# 000664, Jackson Lab). For the pharmacological inhibition studies, we used EDNRB-specific blocker BBQ788^and endothelin receptor non-specific blocker BBosentan.^We believe that the drug BQ-788 would mimic EdnrB KO mice and the use of Bosentan would help decipher the involvement of other subtype, i.e., EdnrA. A pilot study with different doses of BQ-788 (at 0.5 and 1.0 mg/kg) and Bosentan (at 25 and 50 mg/kg) was initially conducted to estimate the dose-response activity. For the final experiment, we used 0.5 mg/kg of BQ-788 and 50 mg/kg Bosentan. Animals were randomly assigned to three different groups. Group I (n = 5) was injected with carrier, group II (n = 6) with Bosentan (50 mg/kg), and group III (n = 5) with BQ-788 (0.5 mg/kg). In total, all groups were injected four times at 48-h interval with respective dosages. The baseline measurements, i.e., 21% O 2 , was carried out after 2 h of 4th dose injection.
Mice surgical preparation
The IACUC approved the experimental protocol (protocol S04052 and S11306). The animals were anesthetized with an i.p. injection of sodium pentobarbital (50 mg/kg). Mice were prepared for cardiac output (CO) measurements by first surgically implanting a jugular catheter (PE10 filled with heparin/saline solution 30 IU/mL) and a small thermocouple (IT18T75, Physitemp Instruments). A midline incision was made in the exposed area and the right jugular vein and carotid artery were exposed. The thermocouple probe was inserted approximately 0.7 cm into the carotid artery. The tip of the jugular vein catheter was inserted past the subclavian branch of the vein. The temperature probe and PE10 catheter were under the skin on the animal's back. A short femoral catheter (PE10 filled with heparin/saline solution 30 IU/mL) was also implanted to monitor blood pressure and withdraw blood samples, which was secured underneath the skin. Mice recovered from catheter implantation for 24 h before the hypoxia protocol. Mice were suitable for the experiments if (i) systemic parameters were within normal range, namely, heart rate (HR)> 450 beat/min, mean arterial blood pressure (MAP) > 90 mmHg, systemic Hct > 42%, and arterial O 2 partial pressure (p a O 2 ) > 80 mmHg.
Cardiac output measurements
CO was measured by a modified thermodilution technique [13] . Briefly, a saline bolus indicator (0.1 mL at 25°C) was injected via the jugular vein catheter, and the change in temperature was detected at the aortic arch using the implanted thermocouple. This procedure was selected because in these small awake animals, it is not feasible to inject the indicator directly into the right atrium. The conversion of the area under the indicator dilution temperature curve into flow was done with a fluid circuit that reproduced flow rates, volumes, and heat exchange properties of the mice circulation between the locations of saline injection and temperature measurements. Thermodilution curves peaked rapidly and decayed exponentially. The signal due to recirculation was eliminated by truncating the curve 30-50% after the maximum change in temperature. Thermodilution curves area is proportional to CO. Cardiac index (CI) was calculated as the CO divided by the animal body weight.
Hypoxia protocol
The awake animals were placed in a restraining tube within seal acrylic box (4″ × 4″ × 10″). The inlet of the box was connected to gas tanks with different O 2 concentrations: (1) compressed air, (2) 15% O 2 balance N 2 , (3) 10% O 2 balance N 2 , and (4) 5% O 2 balance N 2 . The gas flow rate into the box was kept at 0.2 L/min using a gas flow meter. Air coming into the box was warmed to 25°C and diffused using a cotton filter. O 2 concentration in the box was measured continuously using an O 2 gas sensor (Vernier Corp. Beaverton, OR). Mice were first exposed to compress air and given 20 min to adjust to the experimental environment before baseline measurements were completed. Then, the compressed air was replaced by 15% O 2 , and mice were given 15 min to adjust to the change ) KO mice. c Gel picture depicting tamoxifen induced exons 3-4 deletion in the heart in the gas environment before measurements. Similarly, the 15% O 2 gas was replaced for the 10% O 2 gas, and another 15 min were given to the mice before measurements. Lastly, the 10% O 2 gas was replaced for the 5% O 2 gas, and another 10-15 min were given to the mice before measurements. At each time point, systemic parameters and blood gas analysis were performed which also included lactate level measurements. Briefly, a capillary blood sample was taken from the femoral artery catheter~15 mins after animals were exposed to specific oxygen concentrations. Blood samples were immediately analyzed in a blood gas analyzer (ABL90 FLEX analyzer Radiometer America Inc., Brea, CA). To prevent animal stress or discomfort, hypoxia was stopped if BP dropped below 40 mmHg, and the animal was excluded from the study.
Data analysis
Results are presented as means ± standard deviations. The Grubbs' method was used to assess closeness for all measured parameter values at baseline. Data comparison between groups was analyzed using two-way analysis of variance (ANOVA) with genotype as a between factor and hypoxia treatment as a repeated measure. Data within each group was analyzed using Kruskal-Wallis one-way ANOVA. When appropriate, post hoc analyses were performed with the Dunn's multiple comparison test and Bonferroni post-tests comparison. All statistics were calculated using Analyze-it for Microsoft excel 4.18.1 (Analyze-it Software, Ltd.). Changes were considered statistically significant if P < 0.05.
Results
Generation of cardiac-specific EdnrB KO
We hypothesized that decreasing functional EDNRB specifically in the heart would be advantageous in hypoxia, and hence, we generated cardiac-specific KO mice of this gene and then studied its phenotype in both normoxia and hypoxia. While the generation of EdnrB-LoxP (EdnrB flox/flox ) mice has been previously reported [11] , a detailed schematic of the crosses to generate EdnrB KOs in the cardiomyocytes is presented in Fig. 1b ;Myh6-cre'-' (cre-negative) mice were also injected with equal dosages, i.e., 3 × 30 mg/kg of tamoxifen (Fig. 1b, c) . At the end of the experiment, the brain, lung, and heart were collected for DNA isolation and PCR confirmation of the cardiac-specific EdnrB KO (EdnrB ). Genotype of the brain, lung, and heart confirms exons 3-4 deletion in the heart and not in other tissues or the heart of tamoxifen-treated crenegative mice (Fig. 1c) (Fig. 2a) , the CI in EdnrB flox/+ and EdnrB flox/flox were significantly higher at 10% and 5% O 2 when compared to the control mice ( , which is significantly higher than the cre-negative control group with 0.26 ± 0.02 and 0.18 ± 0.02 mL/min/g (Fig. 2a) Fig. 1S ) and the relative drop from its 21% O 2 was significant when compared with the controls (supplementary Fig. 1S) . Additionally, the lactate levels strongly correlated with the hypoxia tolerance observed in EdnrB flox/+ and EdnrB flox/flox (Fig. 2b) . The lactate levels at 5% O 2 in both EdnrB flox/+ and EdnrB flox/flox (P < 0.05) and at 10% O 2 in EdnrB flox/+ (P < 0.05) were significantly lower than the cre-negative mice at respective O 2 levels. This is also supported by the trends between the three groups with levels in cre-negative > EdnrB flox/ flox > EdnrB flox/+ both at 10% and 5% O 2 , which is inversely related to the CI and CO measurements ( Fig. 2b and  supplementary Fig. 1S ).
EDNRB-specific blocker depict maximum hypoxia tolerance
In order to systematically evaluate the protective role of relatively lower EDNRB in a hypoxic environment, we utilized both non-specific (Bosentan, blocks both EDNRA and EDNRB) and specific (BQ-788) blockers of EDNRB. Adult C57BL/6 J mice were randomly assigned to three different groups. Group I (n = 5) was treated with carrier, group II (n = 5) was treated with Bosentan (50 mg/kg), and group III (n = 5) was treated with BQ-788 (0.5 mg/kg). Cardiovascular functions were measured utilizing modified thermodilution technique (BMaterials and methods^section). Remarkably, both Bosentan and BQ-788 rescue mice by maintaining better cardiac functions under extreme hypoxia. Under ambient conditions, i.e., at 21% O 2 , and also at 15% O 2 , the CI was comparable in all the three groups (Fig. 3a) . However, at 10% and 5% O 2 , a clear trend was seen where the CI was in the ascending order from controls < Bosentan < BQ-788. Under extreme hypoxia of 5% O 2 , the CI was highest for BQ-788-treated mice with P value < 0.005 when compared to the controls and P value < 0.05 when compared with Bosentan-treated mice (Fig. 3a) . On the contrary and as anticipated, the lactate levels at 10% O 2 followed a reverse order with BQ-788 < Bosentan < controls. The differences between the groups were further cumulated at 5% O 2 (P < 0.0001, Fig. 3b ). At this O 2 , the mice treated with BQ-788 had only 44.2% increase in the lactate levels from the level detected at 21% O 2 . This level was lower than Bosentan-treated mice with 62.3% increase and control mice with 77.4% increase. Of note, the BQ-788-treated mice had higher mean arterial pressure, higher heart rate, and lower stroke volume (supplementary Fig. 2S ) and these trends are similar to our findings in EdnrB −/+ mice.
Discussion
EDNRB was one of the top candidate genes we identified in our whole-genome sequence analysis for hypoxia adaptation in Ethiopian highlanders [1] . This was primarily marked by a strong signature of positive selection where large block containing SNPs were fixed in the highlanders but were at a significantly lower frequency in nearby lowlander populations. Subsequently, our findings in EdnrB −/+ mice exquisitely depicted that these mice were resistant to various levels of hypoxia, maintained higher CO, peripheral perfusion, and better O 2 delivery to vital organs, even in severe hypoxia [3] . In other words, by downregulating EdnrB, mice were able to conserve cardiac function when exposed to extreme hypoxia. There is other evidence also demonstrating the advantages of lower EDNRB in the heart. For example, a lower EDNRB in patients with ischemic heart disease is thought to be beneficial [14, 15] . The EDNRB receptor is a G protein-coupled receptor that activates a phosphatidylinositol-calcium (Ca 2+ ) second messenger system [16] . The gene is express in most tissues (Fig.4a) . Functionally, EDNRB is involved in vasodilatation, opposing EDNRA, which is involved in vasoconstriction [17] . However, the role of EDNRB is much more complex than was originally anticipated. During early development, it plays a critical role throughout neural crest cells migration, proliferation, and differentiation [18] . Its disruption leads to phenotypes like Hirschsprung's disease and megacolon [19, 20] . Recent studies specifically involving spatiotemporal KO of EdnrB in mice have depicted a variety of roles it can play in different tissues (Fig. 4b) . Interestingly, most of the phenotypes affected are directly or indirectly related to cardiovascular function or hypoxia response (Fig. 4b) . For example, its direct involvement in blood pressure (BP) or sodium retention was depicted in the collecting duct-specific KO mice [21] and not in the endothelial cell-specific KO [11] , unlike previously anticipated. The contribution of endothelial cells' EdnrB in BP regulation, however, is indirect as it mediates nitric oxide release and responsible for ET-1 clearance from the circulation [22, 23] . At the same time, the EdnrB in smooth muscle contributes to an increased BP but surprisingly had no role in vascular contraction [24] . Even in our previous study on EdnrB −/+ mice, the BP was consistently higher but we did ), and cre-negative control mice. a Both EdnrB flox/flox and EdnrB flox/+ mice maintains a higher CI under extreme hypoxia of 10% and 5% O 2 . b Lactate levels were significantly lower in EdnrB flox/+ mice at 10% and 5% O 2 when compared with the cre-negative group and in EdnrB flox/flox at 5% O 2 . The trends were inversely related to the CI where it is high in the cre-negative controls, medium in the EdnrB flox/flox group, and low in the EdnrB flox/+ group. Error bar indicates ± standard error not observe any increase in circulating ET-1 [3] . To summarize, an overview of whether EDNRB is expressed in the particular tissues and major phenotype observed when the gene is KO in that specific tissue is simplified in Fig. 4 . EdnrBs' involvement in cardiac function, especially in extreme hypoxic stress, has been an important issue because of the maintenance of cardiac function in EdnrB −/+ . Available literature suggests that all the major components of the endothelin system, Edn1, EdnrA, and EdnrB, are expressed in cardiomyocytes. Although Edn1 expression is reportedly necessary for cardiomyocyte's survival and maintenance of normal cardiac function, even during stressful conditions [25] , we did not observe any difference in its level in the EdnrB −/+ mice at baseline [3] . Of the two receptors, only
EdnrB was reportedly present on the cardiomyocytes' nuclear membrane and was associated with regulation of nuclear Ca 2+ signaling [26] . This may be an indication of the important role it plays in contractility. In addition, another study just confirmed the role of nuclear membranes' EDNRB in Ca 2+ signaling [27] , but the authors noted this in endocardial endothelial cells of human left ventricles. From our present study, it is clear that the EdnrB in cardiomyocyte has an important role in maintaining cardiac contractility especially under acute stressful condition, i.e., severe hypoxia. We used inducible Lactate levels at 10% O 2 show a trend towards where it is high in the controls, medium in the Bosentan-treated mice, and low in the BQ-788-treated mice. The difference is significant (P < 0.005) between all the three groups. The error bar indicates ± standard error cardiomyocyte-specific driver because our intention was to KO EdnrB only in the adult cardiomyocytes to avoid the spatiotemporal complexities related to its diverse role (as depicted in Fig. 4b) (Fig. 2a) with lower lactate levels (Fig. 2b) , and the differences were profoundly visible particularly at 5% O 2 . Interestingly, the current study also indicates that, while the cardiomyocytes' EdnrB makes a significant contribution to hypoxia tolerance by protecting the heart during hypoxia by maintaining CI, it does not fully account for the whole phenotype that we observed in the EdnrB −/+ . For example, the higher MAP is seen in EdnrB −/+ but not in the cardiomyocyte-specific EdnrB downregulation. Only at 10% O 2 was the SPB and DBP differs between EdnrB flox/+ and controls. Finally, our current study using EDNRB blocker comprehensively illustrates the protective role of lower EDNRB under extreme hypoxia. Data from the literature show that both Bosentan and specific blockers of EDNRA prevent the increase in pulmonary artery pressure during hypoxia and help in the restoration of oxygen saturation [28] [29] [30] [31] . Since CI is maintained during hypoxia and lactate levels are lower in the EDNRB-specific blocker (BQ-788)-treated mice, we suggest that both EDNRA and EDNRB are involved in hypoxia tolerance. However, in this study, which focuses on cardiac measurements, we demonstrate that cardiac-specific EDNRB (EdnrB flox/+ and EdnrB flox/flox ) are involved in maintaining cardiac output.
Given that EDNRB was first identified in human HA dwellers from Ethiopia known to be best adapted to HA [32] , it is interesting to note a recent study showing that the level of EDNRB in serum was significantly higher in chronic mountain sickness (CMS) patients [33] . Furthermore, the cerebrovascular reactivity (CRV), i.e., the change in cerebral blood flow in response to a stimulus, was reportedly lower in these patients pretty much similar to patients with cardiac failure [34] . This is an interesting observation because (i) we anticipated lower EdnrB to be protective at HA and higher as seen in CMS is deleterious. (ii) This was a study done in Tibetan HA population and we discovered EDNRB as a candidate gene in the Ethiopian HA natives where no case of CMS was ever reported. Therefore, it will be interesting to explore the differences in genetic variants at this locus between these two populations. (iii) A lower CRV, as depicted in cardiac failure patients, possibly indicates that the heart in these CMS patients is less efficient. And we know from our study, both global and cardiac-specific EdnrB KO mice, that a lower EdnrB under hypoxic environment could lead to a better cardiac function. Furthermore, similar to our EdnrB study, the ET-1 levels were similar when CMS subjects were compared to controls. Alternatively, the higher EDNRB in CMS can also be correlated with the inhibitory role of EDNRB in suicidal erythrocyte deaths and therefore preventing Beryptosis^ [35] . In other words, a higher EDNRB in CMS may be inducing polycythemia while a lower level plausibly promoting eryptosis and lowering the abnormally high hematocrit levels.
In summary, it is reasonable to conclude that by lowering EdnrB, genetically or pharmacologically, plays an important role in hypoxia tolerance. Specifically, the cardiomyocyte EdnrB plays the major role in hypoxia tolerance in the EdnrB −/+ mice model. And when we connect to a comprehensive role of EDNRB at HA, it appears that the protective role of a lower EDNRB is potentiated through its two-pronged hypoxia-tolerance strategy, i.e., by (i) sustaining cardiac function, as seen in EdnrB KO-and BQ-788-treated mice under extreme hypoxia and (ii) preventing hypoxia-induced excessive erythrocytosis. This may indicate better adaptation in the HA Ethiopians or lack of CMS thereof. An important question that remains unclear is related to the molecular mechanisms leading to protection against hypoxic injury. Since we now have the crystal structures of EDNRB in both ligand-free form and in complex with EDN1 [36] , progress towards novel therapies is possible.
